Rotating Pazopanib and Everolimus to Avoid Resistance

Exclusion Criteria

• •Prior malignancy.
• •History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis.
• •Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding.
• •Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.
• •Presence of uncontrolled infection.
• •Known past or present infection with Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human Immunodeficiency Virus (HIV).
• •Corrected QT interval (QTc) \> 480 msecs using Bazett's formula.
• •History of one or more of the following cardiovascular conditions within the past 6 months:
• •1. Cardiac angioplasty or stenting
• •2. Myocardial infarction
• •3. Stable or unstable angina pectoris.
• •4. Coronary artery bypass graft surgery.
• •5. Symptomatic peripheral vascular disease
• •6. Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
• •Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of ≥160 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg\].
• •History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
• •Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any nonhealing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major).
• •Evidence of active bleeding or bleeding diathesis.
• •Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.
• •Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug.
• •Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
• •Unable or unwilling to discontinue use of prohibited medications or modify the dosing of interacting drugs for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.
• •Pregnant or lactating female.
• •Treatment with any of the following anti-cancer therapies: Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of Pazopanib OR Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy.